A. Pike

发表

Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray.

F. de Longueville, V. Bertholet, D. Surry, 2002, Biochemical pharmacology.

The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors.

S. Venkatraman, S. Munshi, A. Pike, 2008, Bioorganic & medicinal chemistry letters.

An evaluation of a low-density DNA microarray using cytochrome P450 inducers.

F. de Longueville, V. Bertholet, G. Meneses‐Lorente, 2003, Chemical research in toxicology.

Pyridones in drug discovery: recent advances.

A. Pike, Y. Zhang, 2021, Bioorganic & medicinal chemistry letters.

Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.

A. Pike, H. Broughton, I. Collins, 1999, Journal of medicinal chemistry.

Imidazo[1,2-b][1,2,4]triazines as α2/α3 subtype selective GABAA agonists for the treatment of anxiety

S. Tye, A. Pike, J. Atack, 2006 .

TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates

G. Dawson, S. Tye, R. Mckernan, 2006, Journal of Pharmacology and Experimental Therapeutics.

Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligands

R. Mckernan, A. Pike, J. Atack, 2007, Biopharmaceutics & drug disposition.

Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.

G. Dawson, R. Mckernan, A. Pike, 2004, Journal of medicinal chemistry.

Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.

A. Pike, J. Atack, K. Wafford, 2006, Bioorganic & medicinal chemistry letters.

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.

Peng-Fei Wang, A. Pike, A. Bloecher, 2021, Journal of medicinal chemistry.

Imidazo[1,2-a]pyrimidines as Functionally Selective and Orally Bioavailable GABAAα2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Joanna Stanley, A. Pike, J. Atack, 2006 .

Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.

A. Pike, R. Ternansky, F. T. Counter, 1993, Journal of medicinal chemistry.

Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in

C. D. Jones, A. Pike, M. Jevnikar, 1984, Journal of medicinal chemistry.

Cycloaddition reaction with methylnitrone

A. Pike, E. J. Fornefeld, 1979 .

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .

J S Ward, F. Bymaster, A. Pike, 1992, Journal of medicinal chemistry.

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.

Fiona Pachl, A. Pike, M. O’Connor, 2021, Journal of medicinal chemistry.

7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.

G. Dawson, R. Mckernan, A. Pike, 2005, Journal of medicinal chemistry.

1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.

P. Leeson, A. Pike, C. Moyes, 1999, Journal of medicinal chemistry.

The discovery and evaluation of diaryl ether heterocyclic sulfonamides as URAT1 inhibitors for the treatment of gout

R. M. Owen, A. Pike, M. Bictash, 2016 .

A Pyridazine Series of α2/α3 Subtype Selective GABAA Agonists for the Treatment of Anxiety

S. Tye, A. Pike, J. Atack, 2006 .

Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.

S. Tye, A. Pike, J. Atack, 2006, Journal of medicinal chemistry.

The role of GABAAβ2 subunit‐containing receptors in mediating the anticonvulsant and sedative effects of loreclezole

A. Pike, T. Rosahl, K. Wafford, 2006, The European journal of neuroscience.

Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as α2/α3 subtype selective GABAA agonists for the treatment of anxiety

A. Pike, J. Atack, K. Wafford, 2006 .

Imidazo[1,2-a]pyrazin-8-ones, Imidazo[1,2-d][1,2,4]triazin-8-ones and Imidazo[2,1-f][1,2,4]triazine-8-ones as α2/α3 Subtype Selective GABAA Agonists for the Treatment of Anxiety.

A. Pike, J. Atack, K. Wafford, 2006 .

Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase.

A. Pike, N. Stamm, B. Neubauer, 1993, Journal of medicinal chemistry.

Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines.

F. Bymaster, A. Pike, C. Mitch, 1992 .

3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for α2/α3-Subtypes of Human GABAA Receptor-Ion Channels

G. Dawson, R. Mckernan, A. Pike, 2002 .

A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

S. Tye, A. Pike, J. Atack, 2006, Journal of Medicinal Chemistry.

Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus.

A. Pike, R. Ternansky, S. Draheim, 1993, Journal of medicinal chemistry.

Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.

A. Pike, H. Burns, T. Hamill, 2010, ACS medicinal chemistry letters.

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

P. A. Bradley, Brian E Marron, Ian K Gurrell, 2017, Journal of medicinal chemistry.

ANTIESTROGENS. 2. STRUCTURE-ACTIVITY STUDIES IN A SERIES OF 3-AROYL-2-ARYLBENZO(B)THIOPHENE DERIVATIVES LEADING TO (6-HYDROXY-2-(4-HYDROXYPHENYL)BENZO(B)THIEN-3-YL)-(4-(2-(1-PIPERIDINYL)ETHOXY)PHENYL)METHANONE HYDROCHLORIDE (LY 156758

Charles David Jones, A. Pike, J. Clemens, 1985 .